NanoVibronix (NSDQ:NVBXU) today released interim trial results from a study of its UroShield ultrasound device designed to prevent bacteria and biofilms from forming on urinary catheters, touting significant reductions in bacterial numbers.
The study, which currently has 22 patients, compared patients treated with placebo devices to those with the UroShield. Upon initiation, each patient in the trial exhibited significant microorganism colonization in both the device and retained urine, the Elmsford, Mass.-based company said.
After 30 days, control patients exhibited a similar amounts of indwelling microorganisms, while patients treated with the UroShield showed significant reductions of greater than 90%, teh company said. None of the patients treated with the UroShield had developed clinical infections at 6 days, while 2 patients in the control arm were treated for clinical infections.
“We are very excited to report the results of this latest study, which reinforces our earlier pre-clinical data demonstrating a significant reduction in bacterial colonization on catheter devices when using UroShield. We are not aware of any other effective options for prevention of catheter-acquired urinary tract infections, which represents a major health concern both in the U.S. and around the world. In fact, according to the Centers for Disease Control and Prevention, urinary tract infections are the most common type of health care-associated infection, accounting for more than 30 percent of health care-associated infections reported. Among UTIs acquired in hospital settings, 70 to 80 percent are associated with an indwelling urinary catheter. CAUTI has been associated with increased morbidity, mortality, hospital cost and length of stay. I am pleased to see further strong evidence of UroShield’s ability to lower bacterial colonization, as well as prevent pain, discomfort, and prolonged antibiotic use. We believe our device can improve quality of life for patients and reduce healthcare-costs in all care settings,” CEO Brian Murphy said in a press release.
Last month, NanoVibronix said it was looking to raise approximately $9.6 million in a new offering of shares to support getting its shares listed on the Nasdaq Capital Markets, according to an SEC filing.